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1. Introduction 
Liver biopsy is important in the perioperative management of liver transplantation with 
regard to the preoperative evaluation of donor liver graft, especially to rule out steatotic 
liver, and the postoperative diagnosis of acute cellular rejection (ACR), especially to 
differentiate ACR from other causes of liver dysfunction. In both situations, liver biopsy is 
mandatory to confirm the diagnosis. 
The recent increases in metabolic syndrome and diabetes mellitus in the general population 
have led to an increased incidence of liver steatosis, even in donors without a history of 
excessive alcohol intake. Nonalcoholic fatty liver disease (NAFLD) includes a broad 
spectrum of liver injuries that resemble alcoholic hepatitis, ranging from simple steatosis to 
nonalcoholic steatohepatitis (NASH). NASH is the progressed stage of NAFLD and further 
progression results in fibrosis and cirrhosis, which might also be an indication for liver 
transplantation. ACR is one of the most serious adverse events after transplantation. It is 
often difficult to distinguish it from recurrent hepatitis C virus (HCV), and prompt 
treatment with an appropriate diagnosis is important.  
In this chapter, the indications for liver biopsy and the histologic findings for the diagnosis 
of NAFLD and ACR are described. 
2. NAFLD 
The pathophysiology of NAFLD is yet to be fully elucidated, although the two-hit story 
proposed by James et al.1 is widely accepted. In their hypothesis, insulin resistance is the 
first hit, resulting in the production and accumulation of triglycerides in the liver due to 
dysregulated lipogenesis and lipolysis. Further, oxidative stress and lipid peroxidation as 
the second hit leads to hepatic injury, inflammation, and fibrosis by multiple cytokines and 
adipokines. The prevalence of NAFLD is therefore associated with metabolic syndrome and 
will thus continue to increase in developed countries. Previous autopsy studies2-6 in Western 
countries reported the incidence of NAFLD as 16% to 64% of the population. The incidence 
in the Asian-Pacific region is also increasing and is currently 10% to 30% 7.  
Therefore, hepatectomy or transplantation for NAFLD related cirrhosis or hepatocellular 
carcinomas will likely increase. In addition, because NAFLD is usually asymptomatic and 
the diagnosis can be confirmed only by biopsy, the possibility to encounter the liver donor 
with NAFLD will also increase. Whether hepatic steatosis is associated with impaired liver 
regeneration or an increased risk of morbidity or mortality after liver surgery is 
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controversial. Selzner and Clavien8 showed impaired liver regeneration in steatotic livers 
using rat models. Similarly, impaired regeneration of steatotic liver after large hepatectomy 
or portal vein ligation was reported in subsequent rat model experiments.9,10 In the clinical 
setting, Kooby et al.11 evaluated the outcomes of hepatic resection in 160, 223, and 102 
patients with no, mild (<30%), and marked (≥30%) steatosis, respectively, and showed that 
preoperative comorbidity, steatosis, blood loss, and resection of one lobe or more were 
independent predictors of postoperative morbidity.  
Vauthey et al. 12 reported that steatohepatitis induced by irinotecan-based chemotherapy is 
associated with an increased risk of 90-day mortality after hepatic resection for colorectal 
metastases. On the other hand, Hussein et al. reported a comparable Ki-67 labeling index 
which is a marker of liver regeneration among three groups of patients with simple fatty liver 
(9 patients), NASH (13 patients), and chronic hepatitis C (25 patients), with a similar degree of 
inflammation. They concluded that liver regeneration in patients with NASH is not altered.13 
The number of patients included in this study was small, however, and no patients underwent 
hepatic resection. Further, the Ki-67 labeling index in patients with NASH was smaller than 
that in patients with fatty liver or HCV, although the difference was not statistically significant. 
Considering that NAFLD is a progressive disease ultimately resulting in liver cirrhosis, liver-
related surgery must be performed with special attention to the patient’s safety. Safety is the 
first priority in any patient, and especially in living organ donors. In general, most 
transplantation centers do not accept live donors with histologic liver steatosis of greater than 
30%.14,15 Actually one donor death with NASH has been reported15. The controversy 
surrounds whether all liver donor candidates should undergo liver biopsy because diagnosis 
of NAFLD can be made only by histopathologic examination. Body mass index (BMI) is 
widely regarded as a predictor of liver steatosis. Rinella et al.16 reported that no hepatic 
steatosis was observed among biopsy specimens of live-liver donor candidates with a BMI of 
less than 25 kg/m2, while hepatic steatosis was found in 76% of candidates with BMI greater 
than 28 kg/m2. On the other hand, other studies17,18 demonstrated that 7% to 26% of donor 
candidates with a BMI of less than 25 kg/m2 had hepatic steatosis. Yamashiki et al. recently 
proposed the following criteria for donor biopsy: an aspartate aminotransferase/alanine 
aminotransferase ratio of less than 1, BMI of at least 25, and ultrasonography findings 
suggestive of steatosis. Based on these criteria, liver biopsy was indicated for 25% of their 
referred Japanese donor candidates, and hepatic steatosis of at least 10% was revealed in 12% 
of the donor candidates. Further, they evaluated the visceral fat area measured from a single 
CT slice image at the level of the umbilicus. Receiver operating characteristic curve analysis 
showed that a visceral fat area of at least 96 cm2 predicted steatosis of 10% or more with a 
sensitivity and specificity of 78% and 87%, respectively19.  
NASH can be an indication for liver transplantation, but it also can recur or even occur de 
novo in the transplanted liver graft. In general, immunosuppression with corticosteroids, 
calcineurin inhibitors, or silorimus is associated with body weight gain, insulin resistance, 
and hyperlipidemia. Therefore, post-transplant patients are susceptible to developing 
NAFLD. Poodad et al.20 reported de novo NAFLD that occurred within 3 months of liver 
transplantation in 4 of 88 patients. Later, Seo et al.21 evaluated the incidence and predictors 
of de novo NAFLD among 68 recipients. De novo NAFLD was diagnosed in 12 patients 
(18%) based on follow-up biopsy specimens 11 to 51 months after transplantation. NASH 
was diagnosed in 6 patients (9%). Multivariate analyses showed that a BMI increase of more 
than 10% was a risk factor and the use of angiotensin-converting enzyme inhibitors was 
associated with reduced risk of de novo NAFLD. Although NAFLD in one of the patients in 
Poodad’s report showed improvement following treatment with ursodeoxycholic acid 
(UDCA)20, a subsequent randomized control trial22 showed no therapeutic effect of UDCA 
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for the treatment of NASH compared to placebo. To date, there is no established treatment 
to improve NASH, and prevention should be the first priority. 
3. Histology 
The important factor in the diagnosis of NAFLD is the differentiation of NASH from simple 
steatosis or steatosis with inflammation. For this purpose, several scoring systems have been 
proposed to date. 
Histologic characteristics of NASH include (1) macrovesicularsteatosis, (2) hepatocellular 
ballooning and disarray, (3) intra-lobular inflammation, (4) portal tract inflammation, (5) 
Mallory’s hyaline bodies, (6) acidophil bodies, (7) PAS-D Kupffer cells, (8) 
glycogenatednuclei, (9) lipogranulomas, and (10) hepatocellular iron. Brunt et al. evaluated 
these variables semiquantitatively and proposed three grades (mild, moderate, and severe) 
for necroinflammatory changes. Fibrosis was evaluated separately and scored as stage 1, 
zone 3 perisinusoidal/pericellular fibrosis; stage 2, zone3 perisinusoidal/pericellular 
fibrosis with focal or extensive periportal fibrosis; stage 3, zone 3 perisinusoidal/pericellular 
fibrosis and portal fibrosis with focal or extensive fibrosis; and stage 4, cirrhosis23. Promrat 
et al.24 demonstrated the histologic improvement of NASH by pioglitazone, which is an 
insulin-sensitizing agent, and introduced another scoring system. In this system, six factors; 
steatosis, hepatocellular injury (ballooning degeneration /apoptosis/dropout cells), 
parenchymal inflammation, portal inflammation, fibrosis, and Mallory bodies, were 
evaluated and each was scored semiquantitatively from 0 to 4.  
 
Feature Category Score 





  Lobular inflammation 
No foci 0 
<2 foci 1 
2-4 foci 2 
>4 foci 3 




Table 1. Kleiner’s scoring system for the diagnosis of NAFLD. The sum of the scores 
(ranging 0-8): 0-2, not NASH; ≧ 5, NASH 
These scoring systems, however, emphasize NASH and did not encompass the entire 
spectrum of NAFLD. Later, the Pathology Committee of the NASH Clinical Research 
Network proposed a NAFLD activity scoring system that addressed the full spectrum of 
NAFLD and this was reported by Kleiner et al.25 in 2005. In this study, 14 variables in 5 
broad categories; steatosis, inflammation, hepatocellular injury, fibrosis, and miscellaneous 
features, were evaluated in 32 adult and 18 pediatric liver biopsy specimens by 9 
pathologists. Based on the intra-rater and inter-rater agreement analysis and multivariate 
analysis for the association of the variables with a diagnosis of steatohepatitis, the NAFLD 
activity index was defined as the sum of the scores of three variables; steatosis, lobular 
inflammation, and ballooning (Table 1). Although fibrosis is considered an independent 
www.intechopen.com
 
Liver Biopsy in Modern Medicine 6 
predictor, it was not included because it is less a reversible change and more a result of 
disease activity than a feature of injury activity.  
4. Acute cellular rejection 
Acute cellular rejection (ACR) is suspected when liver function tests worsen. At the 
University of Tokyo, liver transplant recipients undergo postoperative blood chemistry 
daily or every other day during hospitalization, and once every 2 weeks or once a month in 
the outpatient clinics. If all liver function data (aspartate aminotransferase, alanine 
aminotransferase, gamma-glutamyltranspeptidase, alkaline phosphatase, and total 
bilirubin) are elevated compared with previous levels and bile duct complications have been 
ruled out by ultrasound, biopsy is indicated. There are no serum markers specific for ACR 
and biopsy is mandatory to confirm the diagnosis. In contrast to biopsy for the donor 
candidates, biopsy for the diagnosis of ACR should not be delayed because ACR may result 
in chronic rejection, which is characterized by ductpenia or atrophy and pyknosis of the bile 
duct epithelium with parenchymal severe cholestasis,26 and graft loss. Because ACR can be 
treated by immunosuppression, prompt and accurate diagnosis is important. 
 
Category Criteria Score 
Portal 
Inflammation 
Mostly lymphocytic inflammation involving a minority of 
the triads. 
1 
Lymphocyte infiltration to most or all of the triads. 2 
Mixed infiltration to most or all of the triads with 




A minority of the ducts are cuffed and infiltrated by 
inflammatory cells and show only mild reactive changes. 
1 
Most or all of the ducts infiltrated by inflammatory cells. 
More than an occasional duct shows degenerative changes. 
2 
As above for 2, with most or all of the ducts showing 





Subendothelial lymphocytic infiltration involving someportal 
and/or hepatic venules. 
1 
Subendothelial infiltration involving most or all of the portal 
and/or hepatic venules. 
2 
As above for 2, with moderate or severe perivenular 
inflammation that extends into the perivenular parenchyma 
and is associated with perivenular hepatocyte necrosis. 
3 
Table 2. Banff scheme for rejection activity index 
In general, the diagnosis of ACR is confirmed and graded into four classes according to the 
Banff scheme27,28 (Grade 0 [G0]: no evidence of rejection; Grade 1 [G1]: mild rejection; Grade 
2 [G2]: moderate rejection; and Grade 3 [G3]: severe rejection). This grading system is based 
on the degree of portal infiltration of lymphocytes (P0-3), bile duct inflammation or damage 
(B0-3), and venous endothelial inflammation (V0-3) (Table 2).  
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5. Eosinophilia as an aid to diagnose ACR 
To facilitate the diagnosis of ACR, the efficacy of blood and/or histologic eosinophilia has 
been reported in several studies29-38 (Table 3). In these studies, sensitivity and specificity of 
blood eosinophilia to predict ACR before biopsy were reported to be 32% to 96% and 63%  to 
97%, respectively, while those of histologic eosinophilia were 54% to 92% and 65% to 98%, 
respectively. Further, the correlation of eosinophilia with the severity of ACR, or a decrease of 
blood eosinophil count in response to treatment was reported in most of these studies39,40, 
although the effect of steroids alone to downregulate eosinophils cannot be ignored. 
 
 
Table 3. Summary of the studies evaluating blood of histologic eosinophila with the 
diagnosis of acute cellular rejection (ACR). AEC, absolute eosinophil count; REC, percentage 
of eosinophil count in the whole leukocyte count. 
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Notably, blood eosinophilia a few days before biopsy is associated with ACR. Although 
rather low sensitivity is a problem, careful monitoring of the differential leukocyte count 
may contribute to the early detection of ACR. On the other hand, histologic eosinophilia 
predicts ACR with rather high sensitivity and specificity. Gupta et al. validated the inclusion 
of eosinophilia in addition to portal inflammation, endothelialitis, and bile duct damage for 
the grading of ACR and proposed the Royal free hospital (RFH) scoring system. In this 
system, the highest eosinophil count in a portal tract is graded as the follows: none (score 0), 
0; mild (score 1), 1-4 cells; moderate (score 2), 5-9 cells; severe (score 3), 10 or more cells.41 
Kishi et al.38 evaluated histologic eosinophilia as the maximum eosinophil count per portal 
tract (Emax) and the rate of portal tracts that included at least one eosinophil (E(+) rate), and 
demonstrated that both were associated with ACR as well as with ACR severity. This 
finding was later validated in another study by Demirhan et al.42, in which marked 
eosinophilia assessed as Emax and E(+) rate correlated with ACR severity and response to 
treatment.  
6. Differentiation from HCV recurrence 
Differential diagnoses of ACR include recurrent or new-onset viral hepatitis by HBV, HCV, 
cytomegalovirus, or Epstein-Barr virus, autoimmune hepatitis, primary biliary cirrhosis, or 
primary sclerosing cholangitis. Among them the differentiation from recurrent HCV is 
difficult especially in the early postoperative period because histologic features overlap43, 
but is critical because the treatment strategy is completely opposite. 
To date, several studies have evaluated the interobserver agreement for the differential 
diagnosis of ACR and recurrent hepatitis C. Regev et al.43 evaluatedthe interobserver and 
intraobserver agreement among five experienced pathologists for the diagnosis of 102 
biopsy specimens. The results indicated that both the interobserver and the intraobserver 
agreement were relatively low, with Kappa scores ranging from 0.20 to 0.24 for 
interobserver agreement and from 0.19 to 0.42 for intraobserver agreement, indicating only 
slight to moderate agreement43. Netto et al.44 reported the results of a multiinstitutional 
study to evaluate the agreement on the diagnosis of 11 biopsy specimens based on the Banff 
schema ACR scoring system and Batts and Ludwig schema for HCV staging by 17 
pathologists. The results showed a Kappa score of 0.62 to 0.76 for interobserver agreement 
on the diagnosis of ACR or HCV, indicating substantial or almost perfect agreement45.  
In general, pathologists tend to over diagnose ACR rather than HCV recurrence. Leung et 
al.46 reported a case of histologically diagnosed ACR that improved only by interferon and 
ribavirin therapy, and suggested that histologic characteristics traditionally associated with 
ACR might represent early recurrent HCV. Barnes et al. reported that HCV-positive patients 
with ACR are less likely to have blood eosinophilia than HCV-negative patients with ACR. 
They thus proposed that the eosinophil response might be suppressed in HCV-positive 
patients with ACR, and that ACR might be overdiagnosed if based on histopathology in 
patients with normal eosinophil levels36. Similarly, Kishi et al.47 reported that HCV-positive 
patients diagnosed with ACR had significantly higher blood eosinophil counts on the day of 
biopsy than HCV-positive patients without ACR. These findings indicate that measures of 
blood eosinophil levels might contribute to the differential diagnosis of ACR in HCV-
positive recipients. 
Several blood or histologic markers have been proposed to facilitate the differentiation 
between ACR and recurrent HCV. Unitt et al.48 reported that minichromosome maintenance 
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protein-2 (Mcm-2) visualized by immunohistochemical staining in lymphocytes infiltrating 
into the portal tracts is more frequently expressed in ACR than in HCV recurrence. The 
number of Mcm-2–positive lymphocytes in the portal tract was not correlated with the ACR 
grade, but a cut-off of 107 positive cells per portal tract distinguished ACR from HCV with a 
sensitivity of 82% and a specificity of 92%. MacQuillan et al.49 performed 
immunohistochemical analysis to evaluate the expression of MxA protein, which belongs to 
the class of guanosine triphosphatases and is a marker of activation of the type 1 interferon 
pathway. The findings demonstrated strong hepatocellular MxA staining in 78% of HCV 
recurrence and in 30% of ACR biopsy specimens.  
Typical histologic features of recurrent hepatitis C include lobular disarray, Kupffer cell 
hypertrophy, hepatocyte apoptosis, mild sinusoidal lymphocytosis, mononuclear portal 
inflammation, macrovesicularsteatosis involving periportal and midzonal hepatocytes. In 
chronic hepatitis, lobular changes wane and portal inflammation increases. Occasionally, 
nodular portal-based lymphoid aggregates are formed with emerging necroinflammatory 
and ductular-type interface activity. Further, fibrosing cholestatic hepatitis (FCH), which is 
clinically featured by rapidly progressive jaundice and extremely high HCV viral loads, may 
occur and is fatal in most cases. The incidence of FCH among the recipients who underwent 
liver transplantation for HCV-related cirrhosis is reported to be 6 to 14%50-52. Histologically, 
FCH is characterized by extensive fibrosis with immature fibrous bands extending from the 
portal tracts to the sinusoidal spaces, prominent canalicular and hepatocellular cholestasis, 
ground-glass transformation, ballooning of hepatocytes with cell loss, and a mild mixed 
inflammatory reaction may occur53. A small case series52,54,55 reported that a certain 
proportion of patients with FCH might respond to interferon plus ribavirin with or without 
conversion of tacrolimus to cyclosporine A. Increased immunosuppression as a treatment 
for ACR is an important cause of FCH56. 
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